Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate

Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con | Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she continues to defend the drug’s data against skepticism.

Raccontata damorningstar.comglobal.chinadaily.com.cnendpoints.newsfiercepharma.comscmp.com